Brief: Oncolytics Says Pelareorep Shows Durable Survival Benefit in Anal Cancer
BRIEF-Oncolytics Says Pelareorep Shows Durable Survival Benefit in Anal Cancer Oct 27 (Reuters) - Oncolytics Biotech Inc ONCY.O:
ONCOLYTICS BIOTECH® REPORTS STRONG DURABILITY AND SURVIVAL DATA IN ANAL CANCER, POSITIONING PELAREOREP AS POTENTIAL BACKBONE IMMUNOTHERAPY ACROSS HPV-DRIVEN CANCERS
Source text: ID:nGNX3lCKL3
Further company coverage: ONCY.O
(Reporting by Zakia Mariyam)
((Zakia.Mariyam@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Announces Clinical Supply Agreement To Evaluate Pelareorep In Combination With Loqtorzi In Squamous Cell Anal Carcinoma
Brief: Oncolytics Says Pelareorep Shows Durable Survival Benefit in Anal Cancer
Brief: Oncolytics Biotech Expects Final Cohort 4 Results Of Goblet Study In Q4 2026
Brief: Oncolytics Biotech® Secures Patent Protection To Late 2040S And Provides Intellectual Property Portfolio Update
Brief: Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer